EP Patent

EP4138843A4 — COMPOSITION FOR TREATING BLOOD CANCER CONTAINING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF

Assigned to Pinotbio Inc · Expires 2024-07-10 · 2y expired

What this patent protects

Patent listed against Vidaza.

Drugs covered by this patent

Vidaza (azacitidine) · Bristol-Myers Squibb

Patent Metadata

Patent number: EP4138843A4
Jurisdiction: EP
Classification: —
Expires: 2024-07-10
Drug substance claim: No
Drug product claim: No
Assignee: Pinotbio Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.